Biotechnology Innovation Organization

Academic discoveries become jobs - and medicines - when companies build the teams, labs, and facilities to carry them forward. That happens in every state and region across the country. Full data in the @BayhDole Coalition's new report: bayhdolecoalition.org/new-report-sho…

New data from BIO’s U.S. bioscience economy report with #CSBA and @TEConomyP_LLC points to what’s ahead for the industry. 📈 Companies have committed to U.S. biomanufacturing projects totaling hundreds of billions of dollars, many still in early building phases, and clinical trials were hosted in every state, D.C. and Puerto Rico from 2021 to 2025. Bio.News looks at what these trends mean for patients, innovators and states.

Read the story: bio.news/state-policy/2…

This year's #BIOPACE26 brought patient advocates, biotech leaders, and policy experts together in Washington, DC - and the momentum from those two days is still with us.

Every advocate in the room represented a patient community, its stories, and the unmet needs that shape the path to new treatments. Thank you for your leadership, your partnership, and for making PACE what it was.

This fall, as we close out IP Month, we’re celebrating something as American as apple pie: the ideas that power American biotech. Strong intellectual property protections are the armor around every breakthrough, giving innovators the confidence to spend the decade-plus and billions it takes to turn an idea into a treatment. It’s also why small and emerging companies - behind the majority of new medicines - can attract the investment to compete at all.

Read more on Bio.News: bio.news/federal-policy…

The FDA has launched the Rare Disease Framework Initiative (“RDF Initiative”) to develop a fit-for-purpose regulatory framework to make drug development more predictable for conditions with small patient populations and limited data. Currently, about 95% of rare disease patients have no approved treatment.

BIO presented recommendations at FDA’s Oct. 28 public meeting. Bio.News has the details: bio.news/federal-policy…